

Nuria Porta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8357937/publications.pdf>

Version: 2024-02-01

58
papers

3,954
citations

304743

22
h-index

233421

45
g-index

58
all docs

58
docs citations

58
times ranked

6500
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. <i>Clinical Cancer Research</i> , 2022, 28, 1323-1334.	7.0	7
2	Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. <i>European Urology</i> , 2022, 82, 273-279.	1.9	29
3	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 566-574.	7.0	50
4	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , 2021, 79, 307-315.	1.9	20
5	Image Contrast, Image Pre-Processing, and T1 Mapping Affect MRI Radiomic Feature Repeatability in Patients with Colorectal Cancer Liver Metastases. <i>Cancers</i> , 2021, 13, 240.	3.7	12
6	Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. <i>British Journal of Cancer</i> , 2021, 124, 1130-1137.	6.4	11
7	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology</i> , The, 2021, 22, 246-255.	10.7	73
8	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021, 11, 2812-2827.	9.4	78
9	Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8012-8012.	1.6	2
10	Reply to Santhanam Sundar and Paul Symonds's Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>Eur Urol</i> 2021;79:307-315. <i>European Urology</i> , 2021, 80, e51-e52.	1.9	0
11	Hypofractionation: less is more?. <i>Oncotarget</i> , 2021, 12, 1729-1733.	1.8	0
12	ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1471-1475.	2.5	30
13	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. <i>Radiology Imaging Cancer</i> , 2021, 3, e210048.	1.6	22
14	815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI). <i>Annals of Oncology</i> , 2021, 32, S768.	1.2	0
15	The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. <i>European Urology</i> , 2020, 77, 344-351.	1.9	41
16	Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e418-e442.	1.9	28
17	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020, 77, 260-268.	1.9	58
18	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	10.7	450

#	ARTICLE	IF	CITATIONS
19	PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 22-28.	1.7	19
20	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycinâ€” vs surgical management in lowâ€”risk nonâ€”muscleâ€”invasive bladder cancer. <i>BJU International</i> , 2020, 125, 817-826.	2.5	27
21	Reply to Wei Liu, Xiaoping Liu, Sheng Liâ€™s Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy Â± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>Eur Urol</i> 2020;77:260â€”8. <i>European Urology</i> , 2020, 77, e156-e157.	1.9	0
22	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 1743-1751.	8.2	180
23	Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2182-2184.	1.6	13
24	Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S138.	0.8	9
25	BOXITâ€”A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). <i>European Urology</i> , 2019, 75, 593-601.	1.9	27
26	TOPARP-B: A phase II randomized trial of the poly(ADP-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5005-5005.	1.6	35
27	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , 2018, 4, 235-244.	3.1	14
28	Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. <i>Radiotherapy and Oncology</i> , 2018, 126, 155-162.	0.6	72
29	Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5013-5013.	1.6	5
30	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). <i>British Journal of Cancer</i> , 2017, 116, 649-657.	6.4	9
31	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	9.4	341
32	Patient reported outcomes following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Presented on behalf of the START Trial Management Group. <i>European Journal of Cancer</i> , 2017, 72, S5-S6.	2.8	0
33	Molecular similarity considerations in the licensing of orphan drugs. <i>Drug Discovery Today</i> , 2017, 22, 377-381.	6.4	9
34	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , 2017, 283, 168-177.	7.3	81
35	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 135-135.	1.6	3
36	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-141.	1.6	2

#	ARTICLE	IF	CITATIONS
37	BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2017, 35, 280-280.	1.6	15
38	Quality of life (QL) of patients (pts) treated for muscle invasive bladder cancer (MIBC) with radiotherapy (RT) +/- chemotherapy (CT) in the BC2001 trial (CRUK/01/004): Analysis of impact of treatment at an individual level.. Journal of Clinical Oncology, 2017, 35, 292-292.	1.6	1
39	Outcome of BC2001 patients (CRUK/01/004) who received neoadjuvant chemotherapy prior to randomization to chemo-radiotherapy (cRT) versus radiotherapy (RT).. Journal of Clinical Oncology, 2017, 35, 298-298.	1.6	27
40	A specific nursing educational program in patients with Cushing's syndrome. Endocrine, 2016, 53, 199-209.	2.3	28
41	Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 5014-5014.	1.6	3
42	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. Journal of Clinical Oncology, 2016, 34, 5043-5043.	1.6	0
43	Abstract 4340: DNA repair genes aberrations in germline DNA in metastatic castration-resistant prostate cancer patients. , 2016, , .		0
44	Abstract 3973: Diffusion-weighted imaging of bone metastases as treatment response biomarker in prostate cancer. , 2016, , .		0
45	2642 The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 (CRUK/01/004) trial. European Journal of Cancer, 2015, 51, S527-S528.	2.8	0
46	Dynamic prediction methods in the BC2001 clinical trial. Trials, 2015, 16, .	1.6	0
47	2507 Prognostic factors in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). European Journal of Cancer, 2015, 51, S475-S476.	2.8	1
48	2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC). European Journal of Cancer, 2015, 51, S504.	2.8	0
49	The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. British Journal of Cancer, 2015, 113, 1275-1281.	6.4	11
50	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
51	Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer. , 2015, , .		2
52	The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation. Journal of Cheminformatics, 2014, 6, 5.	6.1	23
53	Where do new medicines originate from in the EU?. Nature Reviews Drug Discovery, 2014, 13, 92-93.	46.4	34
54	Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. European Journal of Clinical Pharmacology, 2014, 70, 361-367.	1.9	86

#	ARTICLE	IF	CITATIONS
55	GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries?. Diagnostic Microbiology and Infectious Disease, 2013, 75, 325-326.	1.8	14
56	Transplantation: clinical studies - A. Nephrology Dialysis Transplantation, 2013, 28, i275-i292.	0.7	0
57	A dynamic model for the risk of bladder cancer progression. Statistics in Medicine, 2012, 31, 287-300.	1.6	7
58	Discordance between reported intention-to-treat and per protocol analyses. Journal of Clinical Epidemiology, 2007, 60, 663-669.	5.0	149